NeuroSense Therapeutics

NeuroSense Therapeutics (NASDAQ: NRSN) is a late-stage clinical biotechnology company focused on the discovery and development of targeted, innovative therapeutics for severe neurodegenerative diseases. Founded in 2017 by CEO Alon Ben-Noon—inspired by a chance encounter with an ALS advocate—the company operates with a profound mission to address the massive unmet medical needs of patients facing complex conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Operating from its dual headquarters in Herzliya, Israel, and Cambridge, Massachusetts, NeuroSense utilizes a unique approach to drug development: targeting multiple core pathogenic mechanisms simultaneously through synergistic, combined therapeutic strategies.

The company's flagship drug candidate is PrimeC, an advanced, proprietary fixed-dose combination of ciprofloxacin and celecoxib designed specifically to treat ALS. PrimeC tackles key drivers of the disease, including motor neuron degeneration, inflammation, and iron accumulation. The drug has been granted Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and benefits from a robust patent estate extending out to 2042. Recently, PrimeC demonstrated significant efficacy, safety, and tolerability in its PARADIGM Phase 2b clinical trial, successfully highlighting its potential to meaningfully slow disease progression and improve survival rates for those living with ALS.

Moving through late 2025 and into 2026, NeuroSense has rapidly accelerated its clinical and commercial pathways. The company recently reported transformative Phase 2b MicroRNA biomarker data further validating PrimeC as a disease-modifying treatment. Backed by positive FDA feedback regarding its pivotal Phase 3 study design, NeuroSense has also successfully completed commercial manufacturing scale-up. In parallel with its U.S. clinical strategy, the company is actively exploring expedited commercial approval pathways with Health Canada, positioning NeuroSense on the precipice of delivering a life-changing new therapy to the global ALS community.
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.